Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim M Strohmaier

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2009
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasisRobert F Betts, Marcio Nucci, Deepak Talwar, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropeniaJohan A Maertens, Luis Madero, Anne F Reilly, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Pediatrics|March 4, 2009
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patientsTheoklis E Zaoutis, Hasan S Jafri, Li-Min Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2009
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasisRobert F Betts, Marcio Nucci, Deepak Talwar, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2010
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II studyJose M Gatell, Christine Katlama, Beatriz Grinsztejn, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropeniaJohan A Maertens, Luis Madero, Anne F Reilly, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Pediatrics|March 4, 2009
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patientsTheoklis E Zaoutis, Hasan S Jafri, Li-Min Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
The New England Journal of Medicine|July 25, 2008
Raltegravir with optimized background therapy for resistant HIV-1 infectionRoy T Steigbigel, David A Cooper, Princy N Kumar, et al.
The New England Journal of Medicine|July 25, 2008
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionDavid A Cooper, Roy T Steigbigel, Jose M Gatell, et al.
Pageof 2